Cosciens Biopharma
(OTC) CSCIF
Cosciens Biopharma Financials at a Glance
Market Cap
$2.63M
Revenue (TTM)
$8.85M
Net Income (TTM)
$11.21M
EPS (TTM)
$-3.27
P/E Ratio
-0.25
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Price
$1.04
Volume
8,336
Open
$0.98
Price
$1.04
Volume
8,336
Open
$0.98
Previous Close
$1.04
Daily Range
$0.93 - $1.04
52-Week Range
$0.79 - $4.40
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Price
$1.04
Volume
8,336
Open
$0.98
Previous Close
$1.04
Daily Range
$0.93 - $1.04
52-Week Range
$0.79 - $4.40
CSCIF News
Aeterna Zentaris Names New CEO
This Week in Biotech
This Week in Biotech
CSCIF: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cosciens Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
28
CEO
Peter Harry Puccetti, CFA
Website
www.cosciensbio.comHeadquarters
Toronto, ON M5K 1E7, CA
CSCIF Financials
Key Financial Metrics (TTM)
Gross Margin
33%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-122%
Return on Capital
-48%
Return on Assets
-38%
Earnings Yield
-4.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.63M
Shares Outstanding
3.18M
Volume
8.34K
Short Interest
0.00%
Avg. Volume
1.89K
Financials (TTM)
Gross Profit
$3.70M
Operating Income
$14.58M
EBITDA
$12.92M
Operating Cash Flow
$11.83M
Capital Expenditure
$985.68K
Free Cash Flow
$12.82M
Cash & ST Invst.
$10.01M
Total Debt
$2.94M
Cosciens Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.46M
-25.9%
Gross Profit
$848.47K
-58.6%
Gross Margin
34.48%
N/A
Market Cap
$2.63M
N/A
Market Cap/Employee
$65.77K
N/A
Employees
40
N/A
Net Income
$3.04M
+54.8%
EBITDA
$2.92M
+44.1%
Quarterly Fundamentals
Net Cash
$7.06M
-49.8%
Accounts Receivable
$1.73M
-30.1%
Inventory
$1.79M
-33.5%
Long Term Debt
$2.65M
+29.9%
Short Term Debt
$294.47K
-45.7%
Return on Assets
-38.18%
N/A
Return on Invested Capital
-47.57%
N/A
Free Cash Flow
$2.11M
+36.2%
Operating Cash Flow
$2.05M
+31.8%